Kodiak is enrolling patients in the phase ... In the past 30 days, estimates for Vanda Pharmaceuticals’ 2024 loss per share have remained constant at 32 cents. Estimates for 2025 loss per ...

Kodiak is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients ("APIs") into Kodiak's proprietary biopolymer backbone to enable high drug-antibody ...

Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti ...